Physician profile
Casey Reulbach
NPI 1235703042
$595.12
in general payments reported to CMS, 2019-2025
14 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $24.01 · 2024: $94.27 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $137.01 | 2022 | |
| Genentech USA, INC. | $105.55 | 2024-2025 | Itovebi, Kadcyla, Perjeta |
| Merck Sharp & Dohme LLC | $52.64 | 2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals LP | $52.06 | 2025 | Lynparza |
| Beigene USA, INC. | $47.98 | 2023-2024 | Brukinsa |
| Geron Corporation | $31.65 | 2025 | Rytelo |
| Eisai INC. | $26.67 | 2025 | |
| Janssen Biotech, INC. | $24.90 | 2025 | Talvey, Tecvayli |
| Abbvie INC. | $22.20 | 2024 | |
| Glaxosmithkline, LLC. | $21.59 | 2025 | Jemperli, Zejula |
| Incyte Corporation | $20.89 | 2025 | Monjuvi, Niktimvo, Jakafi |
| Celgene Corporation | $19.43 | 2025 | Reblozyl |
| Deciphera Pharmaceuticals INC. | $19.28 | 2025 | Qinlock, Tgct |
| Ibsa Pharma INC. | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Reulbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.